^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    5d
    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=30 --> 57
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna • busulfan
    5d
    TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, Sun Yat-sen University
    New P1 trial • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV
    5d
    Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (clinicaltrials.gov)
    P1/2, N=30, Suspended, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    LDH elevation
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Lymphir (denileukin diftitox-cxdl)
    5d
    RG1125765: Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Osteosarcoma, FIERCe Trial (clinicaltrials.gov)
    P1, N=30, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    FOLR1 ( Folate receptor alpha )
    |
    cyclophosphamide • fludarabine IV
    6d
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Suspended, University of Southern California | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR
    6d
    AMC-112: Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, AIDS Malignancy Consortium | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    6d
    Breakfree-SSc: A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (clinicaltrials.gov)
    P3, N=92, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    New P3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • nintedanib • fludarabine IV • Actemra IV (tocilizumab) • BMS-986353
    6d
    Clinical Study of Novel CAR-ITNK Cells Targeting CD70 and CLL1 for Refractory/Relapsed AML (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Tongji Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    7d
    Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies (clinicaltrials.gov)
    P2, N=209, Recruiting, Hackensack Meridian Health | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV
    7d
    Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201 (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Yonsei University
    New P1 trial
    |
    HER-2 expression
    |
    cyclophosphamide • fludarabine IV
    7d
    A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Zhujiang Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    10d
    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Boston Children's Hospital | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial primary completion date
    |
    TERT (Telomerase Reverse Transcriptase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • DKC1 (Dyskerin Pseudouridine Synthase 1) • ZCCHC8 (Zinc Finger CCHC-Type Containing 8) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion